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GABA inhibitorsAbstract Reduced levels of c-aminobutyric acid (GABA) are cause of quite a many diseases, and it
cannot be directly introduced into the body to enhance its level because of the blood–brain barrier.
Thus the technique used for the purpose involves the inhibition of aminobutyrate transaminase
(ABAT), the enzyme catalyzing its degradation. The structure of human ABAT is not currently
known experimentally, thus, it was predicted by homology modeling using pig ABAT as template
due to high level of sequence similarity and conservation. A series of new c-aminobutyric acid
(GABA) derivatives obtained from 4-(1,3-dioxoisoindolin-2-yl)butanoic acid are used in this study.
These c -aminobutyric acid (GABA) derivatives were used as ligand dockings against human ABAT
as well as pig ABAT receptors.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
c-Aminobutyric acid (GABA) is one of the most commonly
occurring neurotransmitters and a regulator of neuronal activ-
ity in the brain (McGeer et al., 1983). Its degradation involves
catalysis by aminobutyrate transaminase (ABAT, GABA
transaminase, 4-aminobutyrate aminotransferase) during the
ﬁrst step. A fall in GABA levels, compared to the normal,
has been elucidated as an effective symptom for a variety of
neurological disorders (Gunne et al., 1984; Butterworth
et al., 1983), such as Alzheimer’s disease (Aoyagi et al.,
1990), epilepsy (Bakay and Harris, 1981), Parkinson’s disease
(Nishino et al., 1988).
Figure 1 2D structures of GABA derivatives (4a–4m). (4a) 4-(1,3-Dioxoisoindolin-2-yl)-N-phenylbutanamide; (4b) 4-(1,3-Dioxoisoin-
dolin-2-yl)-N-(4-ﬂuorophenyl)butanamide; (4c) N-(4-Chlorophenyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide; (4d) N-(4-Bromophenyl)-4-
(1,3-dioxoisoindolin-2-yl)butanamide; (4e) 4-(1,3-Dioxoisoindolin-2-yl)-N-(4-iodophenyl)butanamide; (4f) 4-(1,3-Dioxoisoindolin-2-yl)-
N-(4-nitrophenyl)butanamide; (4g) 4-(1,3-Dioxoisoindolin-2-yl)-N-p-tolylbutanamide; (4h) 4-(1,3-Dioxoisoindolin-2-yl)-N-(4-ethylphe-
nyl)butanamide; (4i) 4-(1,3-Dioxoisoindolin-2-yl)-N-(4-methoxyphenyl)butanamide; (4j) N-(2,4-Dichlorophenyl)-4-(1,3-dioxoisoindolin-
2-yl)butanamide; (4k) N-(2,4-Diﬂuorophenyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide; (4l) N-(4-Chloro-2-iodophenyl)-4-(1,3-dioxoisoin-
dolin-2-yl)butanamide; (4m) N-(4-Chloro-2-methylphenyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide.
Figure 2 3D structures of template and target proteins, and their superimposition. (a) Structure of pig 4-aminobutyrate-
aminotransferase used as template; (b) Structure of human 4-aminobutyrate transaminase obtained through homology modeling; (c)
template-target superimposition with an RMSD of 0.2 A˚.
S1268 H. Iftikhar et al.Lower esophageal sphincter (LES) is also controlled by
GABA (Cantu et al., 2003). Transient lower esophageal
sphincter relaxations (TLESRs) cause an increase in frequency
of reﬂux episodes (Dent et al., 1988) in people having disease
linked ABAT alleles (Jirholt et al., 2011), are the principal
motility factor in gastro-esophageal reﬂux disease (GERD;
Holloway, 2000) and are reduced by signaling via GABA
receptors (Lehmann, 2009; Beaumont et al., 2008). Mutations
in ABAT, in relation to GERD, are expected to be located in
non-coding regions (Ku et al., 2010). However, the protein
ABAT is known to have some mutations that cause psychomo-
tor retardation and early death (Medina-Kauwe et al., 1999;
Jaeken et al., 1984).
In the case of ABAT inhibition, GABA-driven signaling via
GABA receptors increases as a consequence of a rise in GABAlevels in the synaptic junctions (Jung et al., 1977). Due to the
fact that GABA cannot move across the blood–brain barrier
without signiﬁcant side effects (Toth et al., 1983), so far the
most effective way to retain the levels of GABA is via inhibi-
tion of ABAT by targeting its active site.
This study was performed to analyze the inhibitory effects
of certain experimentally known compounds on human
ABAT, their interaction details and effectiveness. In this study
we have used human ABAT 3D structure as receptor against a
dataset of GABA derivatives obtained from 4-(1,3-dioxoisoin-
dolin-2-yl) butanoic acid. As 3D structure of human ABAT
was not known we have used homology modeling for structure
prediction. Binding site of ABAT was identiﬁed and insilico
analysis was carried out via performing docking studies of
ABAT structures with GABA derivatives. Each docking
Figure 3 Structure validation of modeled protein, human ABAT. (a) Ramachandran plot showing 99% residues in the allowed region;
(b) Procheck validation plot for main chain parameters; (c) Errat quality check with an overall quality factor of 91.372.
In silico analysis of the inhibitory activities of GABA derivatives on 4-aminobutyrate transaminase S1269experiment was analyzed carefully for ﬁnding correct orienta-
tions of ligands with receptor binding site.
2. Materials and methods
2.1. Structure prediction
3D structure of human protein 4-aminobutyrate transaminase
(from here-on referred to as target) is not known experimen-
tally yet. For elucidation of the 3D structure of this protein,
structure of pig 4-aminobutyrate transaminase (PDB ID:
1OHV; Storici et al., 2004; from here-on referred to astemplate) was used as a template with high sequence similarity.
Protein structure prediction, carried out using Swiss-Model
server (Arnold et al., 2006), was followed by model optimiza-
tion and validation using Ramachandran plot (Kleywegt and
Jones, 1996), Procheck, Errat (Colovos and Yeates, 1993),
Verify3D (Luthy et al., 1992; Bowie et al., 1991) and WhatIF
(Vriend, 1990) tools.
2.2. Ligand dataset
Yadav et al. reported a series of new c-aminobutyric acid
(GABA) derivatives obtained from 4-(1,3-dioxoisoindolin-2-
Table 1 Different energy values and Ki values after docking the compounds with receptor protein, human ABAT.
Ligands Binding energy
(kcal/mol)
Ki (lM) Inter-molecular
energy (kcal/mol)
vdW+Hbond + desolv
Energy (kcal/mol)
Electrostatic
energy (kcal/mol)
Final total in rnal
energy (kcal/ ol)
Torsional free
energy (kcal/mol)
Unbound system’s
energy (kcal/mol)
4a 7.13 5.89 8.63 8.44 0.19 0.29 1.49 0.29
4b 7.30 4.48 8.79 8.62 0.17 0.02 1.49 0.02
4c 7.87 1.71 9.36 9.18 0.18 0.16 1.49 0.16
4d 8.04 1.27 9.54 9.29 0.25 0.10 1.49 0.10
4e 7.59 2.74 9.08 8.77 0.31 0.35 1.49 0.35
4f 8.34 0.77 10.13 9.08 1.06 0.41 1.79 0.41
4 g 7.90 1.62 9.39 9.15 0.24 1.39 1.49 1.39
4 h 8.19 0.99 9.98 10.0 0.03 1.48 1.79 1.48
4i 6.89 8.85 8.68 8.48 0.21 0.29 1.79 0.29
4j 7.83 1.81 9.32 9.16 0.16 0.51 1.49 0.51
4 k 7.68 2.35 9.17 8.81 0.36 0.42 1.49 0.42
4 l 7.91 1.60 9.40 9.32 0.07 0.06 1.49 0.06
4 m 8.25 0.90 9.74 9.47 0.27 0.46 1.49 0.46
Table 2 Different energy values and Ki values after docking the compounds with receptor protein, pig ABAT.
Ligands Binding energy (kcal/mol) Ki (lM) Inter-molecular
energy (kcal/mol)
vdW+Hbond + desolv
Energy (kcal/mol)
Electrostatic
energy (kcal/mol)
Final total ternal
energy (kca mol)
Torsional Free
Energy (kcal/mol)
Unbound System’s
Energy (kcal/mol)
4a 7.35 4.09 8.84 8.71 0.13 0.34 1.49 0.34
4b 7.75 2.09 9.24 9.18 0.06 0.23 1.49 0.23
4c 8.67 0.44 10.16 10.25 0.09 1.08 1.49 1.08
4d 9.29 0.16 10.78 10.64 0.14 0.14 1.49 0.14
4e 8.11 1.13 9.61 9.50 0.11 0.14 1.49 0.14
4f 8.92 0.29 10.71 9.99 0.72 0.65 1.79 0.65
4 g 9.15 0.20 10.64 10.38 0.26 0.29 1.49 0.29
4 h 8.69 0.43 10.48 10.41 0.06 0.29 1.79 0.29
4i 7.82 1.86 9.61 9.49 0.12 0.11 1.79 0.11
4j 7.79 1.94 9.28 9.23 0.06 0.25 1.49 0.25
4 k 7.11 6.14 8.60 8.53 0.07 0.52 1.49 0.52
4 l 8.26 0.89 9.75 9.55 0.20 0.09 1.49 0.09
4 m 8.10 1.16 9.59 9.27 0.32 0.44 1.49 0.44
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Figure 4 Binding of all GABA derivatives in (a) template binding site pig ABAT and (b) target binding site human ABAT. Ribbon
represents the receptors while ligands are shown in sticks encapsulated in a mesh.
Figure 5 Residues involved in binding for (a) template and (b) target. All the ligands are shown in sticks enveloped by the mesh surface.
Receptor residues are shown in sticks.
Table 3 Human ABAT active site residues involved in docking interactions with the compounds.
Compounds Binding residues
Gly164 Ser165 Arg220 Asp326 Val328 Gln329 Thr381
4a X X X X X
4b X X X X X X
4c X X X X X X
4d X X X X X X
4e X X X X X X
4f X X X X X
4g X X X X X X
4h X X X X X X X
4i X X X X X X
4j X X X X X
4k X X X X X X
4l X X X X X X
4m X X X X X X
In silico analysis of the inhibitory activities of GABA derivatives on 4-aminobutyrate transaminase S1271yl) butanoic acid by coupling it with various substituted
amines by using DCC as a coupling reagent, which was used
in docking against the target and its template. Fig. 1 shows
2D structures of this series designated as compounds 4a–4m
(Yadav et al., 2012).2.3. Molecular docking studies
Using the toolAutoDock4.2 (Sanner, 1999), automateddockings
were performed for ﬁnding the conformations of selected ligands
(compounds) binding to the active site of 4-aminobutyrate
Table 4 Atoms of the compounds and target protein residues
involved in making hydrogen bonds and bond distance.
Compounds Binding residue Hydrogen bond Distance (A˚)
4a Arg220 O–HN 2.35
O–HN 2.35
Thr381 NH–O 1.82
4b Arg220 O–HN 1.78
O–HN 1.95
4c Arg220 O–HN 2.09
O–HN 2.45
Thr381 NH–O 1.84
4d Arg220 O–HN 2.05
4e Ser165 O–HN 2.11
O–H 2.49
Thr381 NH–O 2.13
4f Arg220 O–HN 1.90
Thr381 O–HN 1.83
4g Arg220 O–HN 2.07
4h Ser165 O–H 2.03
Thr381 NH–O 1.91
4i Ser165 O–HN 2.01
4j Arg220 O–HN 1.79
4k Ser165 O–H 2.12
N–H 3.10
Thr381 O–HN 2.24
4l Arg220 O–HN 2.01
O–HN 2.26
4m Arg220 O–HN 1.78
O–HN 2.13
S1272 H. Iftikhar et al.transaminase. Polar hydrogen atoms were added to the receptor
proteins andKollman charges were alloted. Non-polar hydrogen
atoms, in ligands,weremergedandGasteiger partial chargeswere
assigned. Also, rotations were allowed for ligands’ bonds, and
random orientations and torsions were used during the proce-
dure. AutoGrid was then used to generate grid maps by locating
an80 · 80 · 80 A˚3gridaroundeach receptormodel, separatedby
0.375 A˚. The Lamarckian genetic search algorithm was used by
setting the program to 100 runs, 150 population size, 2.5 · 106 en-
ergy evaluations, 27,000maximum iterations, 0.02mutation rate,
0.80 crossover rate and an RMS tolerance of 1.0 A˚ for cluster
analysis. The most occurring docked conformation with the low-
est binding energy was selected for that particular ligand.
2.4. Binding residues
From PDB (ID: 1OHV), the active site residues of the template
protein were extracted followed by inference of target protein
residues by alignment of the two proteins.
Template: Gly136A, Asp298A, Thr353B, Gln301A,
Ser137A, Arg192A, Val300A.
Target: Gly164, Asp326, Thr381, Gln329, Ser165, Arg220,
Val328.
3. Results and discussion
3.1. 3D structure prediction of human 4-aminobutyrate
transaminase
Crystal structure of pig 4-aminobutyrate-aminotransferase
(PDB ID: 1OHV; resolution 2.30 A˚) was used as templatefor the prediction of 3D model for human 4-aminobutyrate
transaminase. MSA analysis indicated 80% sequence identity
between target and template sequences and an RMSD of
0.2 A˚ between the two models. Fig. 2 shows the protein struc-
tures of template (Fig. 2a) and target protein (Fig. 2b) along
with superimposed pose of both (Fig. 2c).
3.2. Structure validation
Ramachandran plot indicated 99% residues in the allowed re-
gions and none of the active site residues in the disallowed re-
gion. Moreover, parameters like peptide bond planarity, non-
bonded interactions, Ca tetrahedral distortion, main chain H-
bond energy and overall G factor for the predicted structure lie
within the favorable range.
The homology models were further veriﬁed using Errat,
Verify3D and WhatIF tools. Errat scored the overall quality
factor for non-bonded atomic interactions very much above
the accepted range giving a score of 91.3, which represent
the high quality of our predicted model. Fig. 3 shows the struc-
ture validation by Ramachandran plot, Procheck and Errat
programs.
Main chain parameters in terms of conformation of the pre-
dicted model were checked for deviations from the template
using Procheck (Fig. 3b). Verify3D produced averaged data
points with 96.97% residues exhibiting a score above 0.2,
assuring a considerable high model quality. In the case of hu-
man 4-aminobutyrate transaminase, none of the scores for any
residue given by WhatIF was found less than 5.0 indicating
structure reliability. These data indicated that the predicted
model is of good quality to allow further study.
3.3. Molecular dockings
Molecular docking studies were carried out with both target
and template 4-aminobutyrate transaminase. All the com-
pounds were found to strongly inhibit by completely occupy-
ing the active sites in the case of both the target protein, and
its template model. All inhibitors showed low energy values
as indicated in Table 1 for target and for template in Table 2.
The inhibition constant values indicated the efﬁciency of the
compounds to inhibit the protein, especially compounds 4f,
4h, and 4m in the case of target and 4c, 4d, 4f, 4g, 4h, and 4l
in the case of the template. These exceptionally low Ki values
and low energy values prove drug efﬁciency for these
compounds.
For target protein, binding energy values range from 6.89
to 8.34 kcal/mol while for template protein, binding energy
values range from 7.11 to 9.29 kcal/mol. Along with these,
intermolecular energy values, vdW+Hbond + desolv energy
values, electrostatic energy values, internal energy values and
system’s unbound energy also lie in a favorable range for both
target and template as clearly indicated in Tables 1 and 2.
3.4. Binding mode of GABA derivatives
All GABA derivatives bind efﬁciently with binding sites of
pig and human 4-aminobutyrate transaminase. Fig. 4a and
b shows the binding mode of GABA derivatives with pig
4-aminobutyrate transaminase and human 4-aminobutyrate
Figure 6 Interacting residues involved in docking of inhibitors at active site of human ABAT protein (H-atoms are colored gray, O-
atoms red, N-atoms blue, I-atoms purple, C-atoms of inhibitors are colored green while C-atoms of receptor residues are colored yellow,
and hydrogen bonds are shown with green dashed line labeled with distances in A˚). (a–m) Compounds 4a–4mmode of interaction with the
human ABAT protein binding site.
In silico analysis of the inhibitory activities of GABA derivatives on 4-aminobutyrate transaminase S1273transaminase respectively. It is clearly shown that all com-
pounds bind in the same cavity for both template and
target.
Fig. 5 further shows the residues involved in binding with
both template and target receptors. Fig. 5a shows that
Gly136, Asp298, Thr353, Gln301, Ser137A and Arg192residues of template are involved in interaction while Fig. 5b
shows that Gly164, Asp326, Thr381, Gln329, Ser165, and
Arg220 residues of target are involved in interactions.
Human ABAT interaction with the compounds 4a–4m was
analyzed further in detail. Table 3 shows the binding residues’
information for compounds 4a–4m, we observed that all active
S1274 H. Iftikhar et al.site residues for Human ABAT were involved in docking with
nearly all the compounds.
Strong inhibitor binding is also reﬂected by the frequency
of hydrogen bonds as shown in Table 4 and Fig. 6. Com-
pounds 4a, 4c, 4e and 4k each made three hydrogen bonds
with two residues. Ser165, Arg220 and Thr381 of human
ABAT protein were mostly seen in making hydrogen bonds
with these compounds, however, Arg220 was the most fre-
quently occurring residue in hydrogen bonding. The details
of hydrogen bonds formed by the compounds with binding
residues, atoms involved in the bonds and distance are given
in Table 4.
Fig. 6 shows the interacting residues involved in docking of
inhibitors at the active site of human ABAT protein. Com-
pound 4a forms two hydrogen bonds with Arg220 (2.35 A˚
and 2.35 A˚) and a single hydrogen bond with Thr381
(1.82 A˚), while it interacts hydrophobically with Gly164,
Ser165 and Val328 as shown in Fig. 6a. Compound 4b makes
hydrogen bonds with Arg220 (1.78 A˚ and 1.95 A˚) and forms
hydrophobic interactions with Gly164, Ser165, Val328,
Gln329 and Thr381 (Fig. 6b). Compound 4c forms hydrogen
bonds with Arg220 (2.09 A˚ and 2.45 A˚) and Thr381 (1.84 A˚),
while hydrophobic interactions are observed with Gly164,
Ser165, Asp326 and Val328 (Fig. 6c). Compound 4d forms a
single hydrogen bond with Arg220 (2.05 A˚), while Gly164,
Ser165, Asp326, Val328 and Thr381 are shown to form hydro-
phobic interactions as shown in Fig. 6d. Compound 4e shows
hydrogen bonding with Ser165 (2.11 A˚ and 2.49 A˚) and
Thr381 (2.13 A˚), and hydrophobic interactions with Gly164,
Arg220, Val328 and Gln329 (Fig. 6e). Compound 4f is shown
to be involved in hydrogen bonding with Arg220 (1.90 A˚) and
Thr381 (1.83 A˚), and in hydrophobic interactions with Gly164,
Ser165, and Gln329 (Fig. 6f). Compound 4g hydrogen bonds
with Arg220 (2.07 A˚) and forms hydrophobic interactions with
Ser165, Asp326, Val328, Gln329 and Thr381 (Fig. 6g). Com-
pound 4h is shown to form hydrogen bonds with Ser165
(2.03 A˚) and Thr381 (1.91 A˚) and hydrophobic interactions
with Gly164, Arg220, Asp326, Val328 and Gln329 (Fig. 6h).
Compound 4i forms a hydrogen bond with Ser165 (2.01 A˚),
and hydrophobic interactions with Gly164, Arg220, Asp326,
Val328 and Thr381 (Fig. 6i). Compound 4j interacts by form-
ing a hydrogen bond with Arg220 (1.79 A˚), and hydropho-
bically with Ser165, Asp326, Gln329 and Thr381 as shown in
Fig. 6j. Compound 4k makes hydrogen bonds with Ser165
(2.12 A˚ and 3.10 A˚) and Thr381 (2.24 A˚), and hydrophobic
interactions with Gly164, Arg220, Val328 and Gln329 as
shown in Fig. 6k. Compound 4l is shown to have two hydro-
gen bonds with Arg220 (2.01 A˚ and 2.26 A˚), and hydrophobic
interactions with Ser165, Asp326, Val328, Gln329 and Thr381
(Fig. 6l). Compound 4m forms hydrogen bonds with Arg220
(1.78 A˚ and 2.13 A˚), while the residues Ser165, Asp326,
Val328, Gln329 and Thr381 interact in a hydrophobic manner
with the compound (Fig. 6m).
4. Conclusion
This study supported that the anticonvulsant compounds re-
ported by Yadav et al. (2012) prove their in silico inhibitory
activity on human protein 4-aminobutyrate aminotransferase
that can be used in the treatment of epilepsy and some other
diseases. As human ABAT protein structure was not knownexperimentally the homology modeling technique was used
to predict the 3D structure using the known pig ABAT struc-
ture, keeping in view the fact that this protein has high se-
quence similarity and conservation in both human and pig.
Inhibition of the active site residues with high activity, strong
binding, low energy values and inhibition constant showed
that these compounds can be used in drug design against cer-
tain diseases that can somehow be linked to the protein ABAT.
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